Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.
Malignant Tumors
DRUG: Urelumab|DRUG: Nivolumab
Safety of urelumab monotherapy as measured by the dose limiting toxicity (DLT) in subjects with advanced and/or metastatic malignant tumors, From day 1 of treatment up to 60 days of follow-up|Safety of urelumab monotherapy as measured by adverse events (AEs) and serious adverse events (SAEs) in subjects with advanced and/or metastatic malignant tumors, From day 1 of treatment up to 60 days of follow-up|Tolerability of urelumab monotherapy as measured by the DLT in subjects with advanced and/or metastatic malignant tumors, From day 1 of treatment up to 60 days of follow-up|Tolerability of urelumab monotherapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors, From day 1 of treatment up to 60 days of follow-up
Safety of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors, From day 1 of treatment up to 100 days of follow-up|Tolerability of urelumab-nivolumab combination therapy as measured by AEs and SAEs in subjects with advanced and/or metastatic malignant tumors, From day 1 of treatment up to 100 days of follow-up|Cmax (Maximum observed serum concentration) of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|Ctrough (Trough observed serum concentration) of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|Tmax (Time of maximum observed serum concentration) of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|AUC(0-T) [Area under the concentration-time curve from time zero to the last quantifiable concentration] of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|AUC(TAU) [Area under the concentration-time curve in one dosing interval] of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|AUC(INF) [Area under the concentration-time curve from time zero to infinity and the extrapolated area] of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|T-HALF (Elimination half life) of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|CLT (Total body clearance) of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|Vss (Volume of distribution at steady state) of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|AI (Accumulation Index: ratio of AUC(TAU) and Cmax in cycle at steady state to those after the first cycle) of urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 3, 4, 5, 6, 7, 12, 16, up to 60 days of follow up|Cmax of urelumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|Coeff of urelumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|Ctrough of urelumab and nivolumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|Tmax of urelumab and nivolumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|AUC(0-T) of urelumab and nivolumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|AUC(TAU) of urelumab and nivolumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|AUC(INF) of urelumab and nivolumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|T-HALF of urelumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|CLT of urelumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|Vss of urelumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 3, 4, 5, 6, 9, up to 100 days of follow up|Anti-drug Antibody (ADA) status of the subject in response to Urelumab when administered alone, 21 days/cycle for Urelumab monotherapy, Cycle 1, 2, 4, 8, 12, 16, up to 60 days of follow up|ADA status of the subject in response to Urelumab and Nivolumab when co-administered, 28 days/cycle for combination therapy of Urelumab and Nivolumab, Cycle 1, 2, 4, 5, 9, up to 100 days of follow up|Best overall response (BOR) of urelumab monotherapy, Every 6-8 weeks during the treatment period|BOR of urelumab and nivolumab combination therapy, Every 6-8 weeks during the treatment period
The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.